MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

Search

Penumbra Inc

Atvērts

SektorsVeselības aprūpe

311.26 1.14

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

306.55

Max

316.42

Galvenie mērījumi

By Trading Economics

Ienākumi

581K

46M

Pārdošana

15M

355M

P/E

Sektora vidējais

75.179

87.826

Peļņas marža

12.927

Darbinieki

4,500

EBITDA

4M

55M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+9.01% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 17. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3.5B

12B

Iepriekšējā atvēršanas cena

310.12

Iepriekšējā slēgšanas cena

311.26

Ziņu noskaņojums

By Acuity

50%

50%

166 / 372 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Penumbra Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. janv. 23:11 UTC

Peļņas

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

2026. g. 7. janv. 22:55 UTC

Galvenie tirgus virzītāji

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

2026. g. 7. janv. 21:39 UTC

Galvenie tirgus virzītāji

Raytheon Down Following Trump Post Criticizing Company

2026. g. 7. janv. 20:13 UTC

Galvenie tirgus virzītāji

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2026. g. 7. janv. 20:03 UTC

Galvenie tirgus virzītāji

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

2026. g. 7. janv. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. janv. 23:46 UTC

Tirgus saruna

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

2026. g. 7. janv. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

2026. g. 7. janv. 23:34 UTC

Tirgus saruna

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

2026. g. 7. janv. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

2026. g. 7. janv. 22:48 UTC

Tirgus saruna

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

2026. g. 7. janv. 22:46 UTC

Peļņas

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

2026. g. 7. janv. 22:45 UTC

Peļņas

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

2026. g. 7. janv. 22:43 UTC

Iegādes, apvienošanās, pārņemšana

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026. g. 7. janv. 22:42 UTC

Peļņas

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

2026. g. 7. janv. 22:41 UTC

Peļņas

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

2026. g. 7. janv. 22:41 UTC

Peļņas

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

2026. g. 7. janv. 22:40 UTC

Galvenie tirgus virzītāji

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

2026. g. 7. janv. 22:31 UTC

Tirgus saruna

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

2026. g. 7. janv. 22:22 UTC

Tirgus saruna

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

2026. g. 7. janv. 22:01 UTC

Tirgus saruna

Valuations of New Zealand Property Stocks Supportive -- Market Talk

2026. g. 7. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 7. janv. 21:46 UTC

Tirgus saruna

Northern Star's Revised Guidance Looks Achievable -- Market Talk

2026. g. 7. janv. 21:22 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

2026. g. 7. janv. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

2026. g. 7. janv. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

2026. g. 7. janv. 20:29 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie Near Deal for Revolution Medicines -- Update

2026. g. 7. janv. 20:27 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2026. g. 7. janv. 19:58 UTC

Tirgus saruna

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

2026. g. 7. janv. 19:48 UTC

Galvenie tirgus virzītāji

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Salīdzinājums

Cenas izmaiņa

Penumbra Inc Prognoze

Cenas mērķis

By TipRanks

9.01% augšup

Prognoze 12 mēnešiem

Vidējais 344.64 USD  9.01%

Augstākais 388 USD

Zemākais 266 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Penumbra Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

15 ratings

14

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

288.28 / 292.9394Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

166 / 372 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat